Shopping for a stock? Coles could be a $18B trolley filler

|

Published 22-NOV-2018 16:15 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

It’s been 11 years, but Coles Group Limited (ASX:COL) finally returned yesterday to the ASX, trading at $12.90 with an $18 billion market value during a week in which the broader market suffered sharp falls after a global sell-off.

We saw a wave of panic selling across European, Asian and Australian markets, with the local sharemarket falling 1.3% on the day Coles relisted.

Down, down, prices were certainly down.

However, Coles was happy to be back on the boards as its own entity, following a decision from the Supreme Court of Western Australia on Monday to approve a Wesfarmers shareholder vote in favour of the demerger. Coles was de-listed following Wesfarmers’ acquisition of the Coles Group in 2007.

Shares in Coles began trading on the ASX on a deferred-settlement basis.

“We are pleased to be joining the ASX under our own name,” said Coles Chairman, James Graham.

“Listing Coles on the ASX as a standalone business marks the next phase in the evolution of a company that began as a single store in Collingwood 104 years ago. I speak for the entire board when I say it is an immense privilege to be with Coles for such a milestone, and we thank our 480,000-plus new shareholders for joining us on this journey.”

Coles CEO, Steven Cain, said the past 11 years with Wesfarmers had seen Coles transform into a world-class supermarket retailer.

“Our 115,000 team members can take enormous pride that their company is now listed alongside some of the largest and most recognised businesses in Australia.

“We’re all very excited for the next chapter in the Coles story as we deliver on our strategy to make life easier for our customers.”

Coles shares will be transferred to eligible shareholders on 28 November and the shares will trade on a normal settlement basis from 29 November.

In comparison, Wesfarmers (ASX:WES) shares fell by close to 30% to reflect the demerger.

Analysts had predicted a $13-14 range for the newly listed company and expect Coles to trade at a discount of between 5% and 15% to arch rival, Woolworths (ASX:WOW), due to challenges including declining sales momentum and a falling profit from its retail fuel business.

Bank of America Merrill Lynch analyst, David Errington, released a research note on the day of listing, stating that due to lower fuel profits and higher labour costs, “Coles looks to have lost sales growth momentum in the past four weeks”, which he says is a concern coming into Christmas.

This, of course may be offset by the sale of multi-use shopping bags, which is sure to rise over the festive period.

Coles and Woolworths stand to make roughly $71 million in gross profit by replacing free lightweight plastic bags with heavier 15 cent options.

That’s a lot of bags to put the public money in.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X